RedChip Companies, Inc.

09/17/2026

🌍 OBook Holdings (Nasdaq: OWLS) founder and CEO Darren Wang lays out his vision for the future of global payments. Wang points to stock exchanges tokenizing shares and brokerages needing stablecoin gateways as early signs of a much larger shift, one where prediction markets, cross-border payments, and everyday transactions all run on stablecoin rails.

Wang says the goal is to build invisible infrastructure so banks and fintech companies, not just crypto-native platforms, can move money globally with the same ease people expect today. He points to enterprise clients already moving tens of millions of dollars a month through OwlTing's network as an early proof point of that shift.

Watch the full interview: https://redchip.news/4wpqkFT

Cryptopolitan CoinDesk TechCrunch

09/17/2026

Nexalin Technology (Nasdaq: NXL) CEO Mark White explains how a doctor's recommendation turns into in-home treatment with the company's HALO headset.

White describes the process: a patient sets up a telehealth psychiatry appointment through Nexalin's virtual clinic, and the doctor completes a full diagnosis remotely. If the doctor recommends the HALO, the device ships to the patient's home, arriving as soon as the next day. The patient scans a QR code to download the app, enters their patient ID, and the doctor's protocol — uploaded to the cloud during the appointment — loads directly into the headset. White states the doctor can then monitor compliance, check that the equipment is working, and track treatment response throughout the 4-6 week course, all without the patient visiting a clinic.

🔗 Learn more about Nexalin Technology: https://redchip.news/46GWwKv

FierceBiotech Genetic Engineering & Biotechnology PharmaVoice

09/17/2026

🧬 Virax Biolabs (Nasdaq: VRAX): A Clinical-Stage Diagnostics Company Targeting a $25B+ Unmet Need in Post-Acute Infection Syndromes

Up to 21 million Americans are living with Long COVID, ME/CFS, and post-treatment Lyme disease — yet there is currently no widely adopted objective diagnostic test for these conditions.

Virax Biolabs is developing ViraxImmune™, a potential first-in-category immune profiling test designed to objectively assess immune dysfunction in chronic post-infection conditions — with U.S. commercialization planned for 2027.

ViraxImmune™ is informed by UK NHS-linked clinical studies and independent U.S. validation work conducted at Emory University.

🎥 Watch our 30-second investor brief on Virax Biolabs:
https://redchip.news/4wGnWMg

FierceBiotech Genetic Engineering & Biotechnology PharmaVoice

An estimated 21 million Americans are living with post-acute infect...

09/16/2026

🎸 Venu Holding Corporation (NYSE American: VENU): The $200M Amphitheater Playbook Built on Almost No Dilution

In our latest interview, Founder, Chairman, and CEO JW Roth sits down to break down exactly how VENU builds premium, multi-seasonal live entertainment venues without leaning on traditional equity financing — and why cities are competing to bring them to their communities.

🎤 What Roth covers:
- The public-private partnership model: municipalities contribute real estate, cash, and tax incentives in exchange for the economic activity a venue drives — funding a meaningful share of each project without dilution
- How fractional Luxe FireSuite ownership sales and sale-leaseback or PACE financing combine to cover roughly 80% of project cost with minimal equity used
- Why sponsorship and naming rights alone represent about 30% of annual venue EBITDA, with premium food and beverage, parking, and ticketing fees adding further diversification

🔗 Watch the full interview: https://redchip.news/4baCQ4p

Venu Holding Corporation (NYSE American: VENU) Founder, Chairman, a...

09/16/2026

⏳ Starting in 30 Minutes: TransCode Therapeutics (Nasdaq: RNAZ) Investor Webinar

Starting in 30 minutes. Last chance to register for TransCode Therapeutics' RedChip Investor Webinar, going live at 4:15 PM ET. This is your final opportunity to hear the company walk through its RNA delivery platform, its Phase 2a colorectal cancer trial, and the broader oncology pipeline it has built since its IPO.

🔬 What's on the table today:
- First-in-class RNA therapeutic TTX-MC138 met its Phase 1a safety endpoint with no dose-limiting toxicities
- Phase 2a trial is actively enrolling in ctDNA-positive colorectal cancer patients with minimal residual disease
- Diversified three-platform pipeline spans RNA therapeutics, cancer vaccines, and immuno-oncology

Last call — register now before the webinar begins.

🔗 Register here: https://redchip.news/4xAaols

FierceBiotech PharmaVoice

09/16/2026

Learn more & sign up for news alerts:
https://redchip.com/alerts/rnaz

09/16/2026

🧬 TransCode Therapeutics (Nasdaq: RNAZ): Advancing a Novel RNA Therapy for Metastatic Cancer Into Phase 2a

Every year, cancer claims an estimated 10 million lives globally, with roughly 90% of those deaths attributed to metastatic disease. TransCode Therapeutics, founded with top scientists from Harvard Medical School, is developing a disruptive RNA-based approach designed to target the biology behind cancer's spread. The company's lead candidate, TTX-MC138, has moved from a completed Phase 1a trial into a Phase 2a clinical trial in colorectal cancer.

TransCode is working to bring a new therapeutic option to a disease category that remains the leading cause of cancer mortality.

🔗 Watch the full overview: https://redchip.news/4wipo6K

TransCode Therapeutics (NASDAQ: RNAZ) is a clinical-stage company d...

09/16/2026

🔋 Bimergen Energy (New York Stock Exchange American: BESS): Developing Utility-Scale Storage Across Major U.S. Power Markets

Electricity demand from AI and data centers is rising, and grid stability has become a major priority. Bimergen Energy is developing utility-scale battery energy storage projects with a 23-project pipeline totaling ~2.0 GW across key U.S. regional markets (ERCOT, PJM, WECC, MISO).

🔗 Watch our brief overview: https://redchip.news/4aJLsOe

S&P Global Energy Renewables Now TechCrunch

AI and data centers are driving a step-change in electricity demand...

09/16/2026

⏰ One Week Away: New Horizon Aircraft (Nasdaq: HOVR) RedChip Investor Webinar — September 23 at 4:15 PM ET

With one week to go, momentum is building around New Horizon Aircraft's upcoming investor webinar. The Company's Cavorite X7 combines a patented fan-in-wing design with hybrid-electric propulsion, targeting mission-critical markets like defense, medevac, and disaster response where speed and range matter more than urban air taxi infrastructure. Investors who register now will hear management detail the path from prototype testing to full-scale flight in 2027.

Register today to secure your spot before the calendar fills up.
🔗 Register here: https://redchip.news/4zG4sJx

Hangar X Studios Vertical Plus Breaking Defense Royal Aeronautical Society Top Aces

09/16/2026

⚛️ ASP Isotopes (Nasdaq: ASPI): Four plants, one countdown to free cash flow.

💡 CEO Paul Mann confirms Carbon-14 is on track for commercial production around Q2 and Ytterbium-176 around mid-year, with the Virginia Gas Project helium plant targeting Q3. Together, the four startups mark ASPI's shift from R&D to revenue over the next 12-18 months.

🔗 Learn more: https://redchip.news/4wCtBTn

World Nuclear News Renewables PTY LTD Nuclear Energy Institute